ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Competition For Center Grants Higher In FY95, Kimes Tells BSC

November 25, 1994

Latest Statistics Show Decline In Deaths From Breast Cancer

January 13, 1995

Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light

December 5, 2014

Government Remains open Under Budget Agreement; New Deadlines Are Oct. 5 & 19

October 5, 1990

Study Opens For Women At Risk of Ovarian Cancer

October 29, 2004

Komen Foundation Grant Recipients Are Listed

August 13, 1993